Quantcast

Latest NW Bio Stories

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-06-20 08:23:49

Company Refutes Latest Feuerstein False Headline and Attacks BETHESDA, Md., June 20, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted Adam Feuerstein's latest false headline and attack on the Company, and reaffirmed the Company's recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors....

2014-06-16 08:29:01

BETHESDA, Md., June 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been added to two prestigious Russell Indexes: the Russell Global and the Russell 3,000 Indexes. The preliminary announcement was made on Saturday, June 14, 2014, and becomes effective on June 27, 2014. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO The...

2014-05-29 08:30:55

Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May 29, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, refuted the latest blatantly false and misleading statements made by Adam Feuerstein, in an article on Tuesday, May 27....

2014-05-27 08:29:27

Initial Responses Seen Before Patients Have Completed Treatments; BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a summary of initial data to date in its ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors. The Company reported that over 50% of the patients who have completed at least half of...

2014-05-15 08:32:30

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression BETHESDA, Md., May 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company's ongoing...

2014-04-22 08:33:31

Company to Report On Science And Progress Of DCVax-Direct Trial At World's Largest Cancer Conference BETHESDA, Md., April 22, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology...

2014-03-28 12:26:46

Company Reports Phase III Trial Progress, Positive Regulatory and ASCO Decisions; BETHESDA, Md., March 28, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio's public presentation of significant positive news about all of the Company's programs....

2014-03-10 08:30:14

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator BETHESDA, Md., March 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute ("PEI"- the FDA of Germany) of a "Hospital Exemption" early access program under Section 4b of the German Drug Law. Under this...

2013-12-30 08:26:17

First European Patient In Trial Operated On In June, Profiled In BBC Report BETHESDA, Md., Dec. 30, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related